Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2

Future Microbiology

Volumn 6, Issue 3, 2011, Pages 279-294

  Angus, Allan G N ^a   Patel, Arvind H ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

antibodies; AP33; E2; HCV; immunotherapy; neutralization

Indexed keywords

ALBUMIN; ALPHA INTERFERON; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CAPSID PROTEIN; CD81 ANTIGEN; CLAUDIN 1; COMPLEMENTARY DNA; EPITOPE; GENOMIC RNA; GLYCOPROTEIN E2; GLYCOSAMINOGLYCAN; HEPATITIS C VIRUS IMMUNOGLOBULIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OCCLUDIN; PEGINTERFERON; RIBAVIRIN; SCAVENGER RECEPTOR B; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VARIANT SURFACE GLYCOPROTEIN; VERY LOW DENSITY LIPOPROTEIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS RNA;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG MEGADOSE; END STAGE LIVER DISEASE; EPITOPE MAPPING; GENOTYPE; GLYCOSYLATION; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LIVER TRANSPLANTATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; RNA SYNTHESIS; SEVERE COMBINED IMMUNODEFICIENCY; VIRION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CONSERVED SEQUENCE; EPITOPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 79953301615     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.11.9     Document Type: Review

References (145)

1. Global Burden Of Hepatitis C Working Group: Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44(1), 20-29 (2004).
2. Lavanchy D: The global burden of hepatitis C. Liver Int. 29(Suppl. 1), 74-81 (2009).
3. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558-567 (2005).
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
5. Choo QL, Richman KH, Han JH et al.: Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA 88(6), 2451-2455 (1991).
6. Robertson B, Myers G, Howard C et al.: Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143(12), 2493-2503 (1998).
7. Gottwein JM, Scheel TK, Jensen TB et al.: Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49(2), 364-377 (2009).
8. Simmonds P, Bukh J, Combet C et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42(4), 962-973 (2005).
9. Simmonds P: Genetic diversity and evolution of hepatitis C virus--15 years on. J. Gen. Virol. 85(Pt 11), 3173-3188 (2004).
10. NIH Consensus Statement on Management of Hepatitis C: NIH consensus and state-of-the-science statements. NIH Consens. State Sci. Statements 19(3), 1-46 (2002).
11. Chen SL, Morgan TR: The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3(2), 47-52 (2006).
12. Soriano V, Peters MG, Zeuzem S: New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48(3), 313-320 (2009).
13. Jaeckel E, Cornberg M, Wedemeyer H et al.: Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345(20), 1452-1457 (2001).
14. Kamal SM, Fouly AE, Kamel RR et al.: Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130(3), 632-638 (2006).
15. Loomba R, Rivera MM, McBurney R et al.: The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment. Pharmacol. Ther. 33(5), 559-565 (2011).
16. Wiegand J, Buggisch P, Boecher W et al.: Early monotherapy with pegylated interferon α-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43(2), 250-256 (2006).
17. McCaughan GW, McGuinness PH, Bishop GA et al.: Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med. J. Aust. 157(4), 231-233 (1992).
18. Berenguer M: Natural history of recurrent hepatitis C. Liver Transpl. 8(10 Suppl. 1), S14-S8 (2002).
19. Brown RS: Hepatitis C and liver transplantation. Nature 436(7053), 973-978 (2005).
20. Shouval D, Samuel D: Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32(6), 1189-1195 (2000).
21. Drummer HE, Maerz A, Poumbourios P: Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS lett. 546(2-3), 385-390 (2003).
22. Hsu M, Zhang J, Flint M et al.: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100(12), 7271-7276 (2003).
23. Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003).
24. Lindenbach BD, Evans MJ, Syder AJ et al.: Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005).
25. Wakita T, Pietschmann T, Kato T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005).
26. Zhong J, Gastaminza P, Cheng G et al.: Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005).
27. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R: Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J. Virol. 81(23), 13168-13179 (2007).
28. Pietschmann T, Kaul A, Koutsoudakis G et al.: Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103(19), 7408-7413 (2006).
29. Yi M, Ma Y, Yates J, Lemon SM: Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81(2), 629-638 (2007).
30. Iro M, Witteveldt J, Angus AG et al.: A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res. 83(2), 148-155 (2009).
31. Houghton M: The long and winding road leading to the identification of the hepatitis C virus. J. Hepatol. 51(5), 939-948 (2009).
32. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 25(277) 570-574 (1997) (5325).
33. Yanagi M, Purcell RH, Emerson SU, Bukh J: Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl Acad. Sci. USA. 94(16), 8738-8743 (1997).
34. Bartenschlager R, Sparacio S: Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus research. 127(2), 195-207 (2007).
35. Lindenbach BD, Meuleman P, Ploss A et al.: Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl Acad. Sci. USA 103(10), 3805-3809 (2006).
36. Bukh J: A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39(6), 1469-1475 (2004).
37. Ploss A, Evans MJ, Gaysinskaya VA et al.: Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
38. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL: Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62(3), 447-456 (1990).
39. Mercer DF, Schiller DE, Elliott JF et al.: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927-933 (2001).
40. Meuleman P, Hesselgesser J, Paulson M et al.: Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology Baltimore, Md. 48(6), 1761-1768 (2008).
41. Vassilaki N, Friebe P, Meuleman P et al.: Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. J. Virol. 82(23), 11503-11515 (2008).
42. Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell RH: Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect. Immun. 41(2), 816-821 (1983).
43. Gastaminza P, Dryden KA, Boyd B et al.: Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J. Virol. 84(21), 10999-11009 (2010).
44. He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH: Determining the size of non-A, non-B hepatitis virus by filtration. J. Infect. Dis. 156(4), 636-640 (1987).
45. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J: Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J. Virol. 84(19), 10159-10168 (2010).
46. Bradley D, McCaustland K, Krawczynski K, Spelbring J, Humphrey C, Cook EH: Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J. Med. Virol. 34(3), 206-208 (1991).
47. Gastaminza P, Kapadia SB, Chisari FV: Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 80(22), 11074-11081 (2006).
48. Andre P, Komurian-Pradel F, Deforges S et al.: Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919-6928 (2002).
49. Chang KS, Jiang J, Cai Z, Luo G: Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81(24), 13783-13793 (2007).
50. Jiang J, Luo G: Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 83(24), 12680-12691 (2009).
51. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU: Apolipoprotein c1 association with hepatitis C virus. J. Virol. 82(19), 9647-9656 (2008).
52. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL: Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 80(5), 2418-2428 (2006).
53. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96(22), 12766-12771 (1999).
54. Germi R, Crance JM, Garin D et al.: Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J. Med. Virol. 68(2), 206-215 (2002).
55. Molina S, Castet V, Fournier-Wirth C et al.: The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46(3), 411-419 (2007).
56. Owen DM, Huang H, Ye J, Gale M Jr: Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394(1), 99-108 (2009).
57. Barth H, Schafer C, Adah MI et al.: Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278(42), 41003-41012 (2003).
58. Koutsoudakis G, Kaul A, Steinmann E et al.: Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80(11), 5308-5320 (2006).
59. Scarselli E, Ansuini H, Cerino R et al.: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19), 5017-5025 (2002).
60. Pileri P, Uematsu Y, Campagnoli S et al.: Binding of hepatitis C virus to CD81. Science 282(5390), 938-941 (1998).
61. Evans MJ, von Hahn T, Tscherne DM et al.: Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007).
62. Benedicto I, Molina-Jimenez F, Bartosch B et al.: The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J. Virol. 83(16), 8012-8020 (2009).
63. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T: Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83(4), 2011-2014 (2009).
64. Catanese MT, Ansuini H, Graziani R et al.: Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84(1), 34-43 (2010).
65. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248), 518-520 (1996).
66. Acton SL, Scherer PE, Lodish HF, Krieger M: Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269(33), 21003-21009 (1994).
67. Bartosch B, Vitelli A, Granier C et al.: Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278(43), 41624-41630 (2003).
68. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A: The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 20(6), 735-737 (2006).
69. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R: T cell response in hepatitis C virus infection. J. Clin. Virol. 32(2), 75-85 (2005).
70. Ishii K, Rosa D, Watanabe Y et al.: High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28(4), 1117-1120 (1998).
71. Lavillette D, Morice Y, Germanidis G et al.: Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79(10), 6023-6034 (2005).
72. Logvinoff C, Major ME, Oldach D et al.: Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl Acad. Sci. USA. 101(27), 10149-10154 (2004).
73. Steinmann D, Barth H, Gissler B et al.: Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J. Virol. 78(17), 9030-9040 (2004).
74. Pestka JM, Zeisel MB, Blaser E et al.: Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007). This study, involving a group of homogenous patients in a long-term follow-up of a single-source outbreak of HCV, suggests that the rapid induction of neutralizing antibodies in the acute phase of infection may contribute to viral clearance.
75. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC: Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136(7), 2377-2386 (2009).
76. Neumann AU, Lam NP, Dahari H et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 282(5386), 103-107 (1998).
77. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R: Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83(11), 5760-5764 (2009).
78. von Hahn T, Yoon JC, Alter H et al.: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132(2), 667-678 (2007). A study of a chronically infected patient demonstrating that the rapidly evolving glycoprotein sequences present within the quasispecies population outpace the neutralizing antibody response.
79. Kato N, Ootsuyama Y, Ohkoshi S et al.: Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. Biochem. Biophys. Res. Commun. 189(1), 119-127 (1992).
80. Kato N, Ootsuyama Y, Tanaka T et al.: Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res. 22(2), 107-123 (1992).
81. Weiner AJ, Brauer MJ, Rosenblatt J et al.: Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180(2), 842-848 (1991).
82. Farci P, Shimoda A, Coiana A et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288(5464), 339-344 (2000).
83. Kato N, Sekiya H, Ootsuyama Y et al.: Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67(7), 3923-3930 (1993).
84. Weiner AJ, Geysen HM, Christopherson C et al.: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl Acad. Sci. USA. 89(8), 3468-3472 (1992).
85. Bankwitz D, Steinmann E, Bitzegeio J et al.: Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84(11), 5751-5763 (2010).
86. Forns X, Thimme R, Govindarajan S et al.: Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl Acad. Sci. USA 97(24), 13318-13323 (2000).
87. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL: Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73(4), 2938-2946 (1999).
88. Tao W, Xu C, Ding Q et al.: A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 395(1), 67-76 (2009).
89. Grove J, Nielsen S, Zhong J et al.: Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82(24), 12020-12029 (2008).
90. Diaz O, Delers F, Maynard M et al.: Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J. Gen. Virol. 87(Pt 10), 2983-2991 (2006).
91. Bartosch B, Verney G, Dreux M et al.: An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79(13), 8217-8229 (2005).
92. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N: High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280(9), 7793-7799 (2005).
93. Meunier JC, Engle RE, Faulk K et al.: Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl Acad. Sci. USA 102(12), 4560-4565 (2005).
94. Dreux M, Boson B, Ricard-Blum S et al.: The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J. Biol. Chem. 282(44), 32357-32369 (2007).
95. Zhang M, Gaschen B, Blay W et al.: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14(12), 1229-1246 (2004).
96. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T: Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81(15), 8072-8079 (2007).
97. Goffard A, Callens N, Bartosch B et al.: Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79(13), 8400-8409 (2005).
98. Goffard A, Dubuisson J: Glycosylation of hepatitis C virus envelope proteins. Biochimie 85(3-4), 295-301 (2003).
99. Helle F, Goffard A, Morel V et al.: The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81(15), 8101-8111 (2007).
100. Helle F, Vieyres G, Elkrief L et al.: Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J. Virol. 84(22), 11905-11915 (2010).
101. Krey T, d'Alayer J, Kikuti CM et al.: The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6(2), E1000762 (2010).
102. Yu MY, Bartosch B, Zhang P et al.: Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl Acad. Sci. USA 101(20), 7705-7710 (2004).
103. Zhang P, Wu CG, Mihalik K et al.: Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl Acad. Sci. USA. 104(20), 8449-8454 (2007).
104. Zhang P, Zhong L, Struble EB et al.: Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl Acad. Sci. USA 106(18), 7537-7541 (2009).
105. Sattentau Q: Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 6(11), 815-826 (2008).
106. Valli MB, Crema A, Lanzilli G et al.: Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. J. Med. Virol. 79(10), 1491-1499 (2007).
107. Valli MB, Serafino A, Crema A et al.: Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J. Med. Virol. 78(2), 192-201 (2006).
108. Witteveldt J, Evans MJ, Bitzegeio J et al.: CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90(Pt 1), 48-58 (2009).
109. Timpe JM, Stamataki Z, Jennings A et al.: Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47(1), 17-24 (2008).
110. Brimacombe CL, Grove J, Meredith LW et al.: Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85(1), 596-605 (2011).
111. Law M, Maruyama T, Lewis J et al.: Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25-27 (2008). A study demonstrating protection afforded by broadly neutralizing antibodies against heterologous virus challenge in a human liver chimeric mouse model.
112. Owsianka A, Tarr AW, Juttla VS et al.: Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79(17), 11095-11104 (2005). The broad neutralization potential of mAb AP33 demonstrated in the HCVpp system.
113. Perotti M, Mancini N, Diotti RA et al.: Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82(2), 1047-1052 (2008).
114. Tarr AW, Owsianka AM, Timms JM et al.: Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43(3), 592-601 (2006). Identification of HCV E2 amino acid residues that are critical for AP33 recognition.
115. Broering TJ, Garrity KA, Boatright NK et al.: Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83(23), 12473-12482 (2009).
116. Gal-Tanamy M, Keck ZY, Yi M et al.: In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc. Natl Acad. Sci. USA 105(49), 19450-19455 (2008). Identification of in vitro selected mAb AP33-escape mutants with impaired infection fitness.
117. Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH: Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J. Virol. Methods 157(1), 69-79 (2009).
118. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH: Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82(Pt 8), 1877-1883 (2001).
119. Vieyres G, Dubuisson J, Patel AH: Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J. Gen. Virol. 92(Pt 3), 494-506 (2011).
120. Tarr AW, Owsianka AM, Jayaraj D et al.: Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J. Gen. Virol. 88(Pt 11), 2991-3001 (2007).
121. Krawczynski K, Alter MJ, Tankersley DL et al.: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J. Infect. Dis. 173(4), 822-828 (1996).
122. Davis GL, Nelson DR, Terrault N et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 11(8), 941-949 (2005).
123. Galun E, Terrault NA, Eren R et al.: Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J. Hepatol. 46(1), 37-44 (2007).
124. Schiano TD, Charlton M, Younossi Z et al.: Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 12(9), 1381-1389 (2006).
125. Eren R, Landstein D, Terkieltaub D et al.: Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80(6), 2654-2664 (2006).
126. Dhillon S, Witteveldt J, Gatherer D et al.: Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J. Virol. 84(11), 5494-5507 (2010). A study describing a set of AP33-escape mutants isolated from cultured cells that show enhanced sensitivity to neutralization by wide ranging neutralizing antibodies.
127. Duan H, Struble E, Zhong L et al.: Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine 28(25), 4138-4144 (2010).
128. Keck ZY, Li SH, Xia J et al.: Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J. Virol. 83(12), 6149-6160 (2009). A study characterizing multiple escape variants to various broadly neutralizing human mAbs in the viral glycoprotein sequences isolated from sequential samples collected over a 26-year period from a chronically infected patient.
129. Feliu A, Gay E, Garcia-Retortillo M, Saiz JC, Forns X: Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl. 10(9), 1131-1139 (2004).
130. Moreno Garcia J, del Campo Terron S, Moraleda Garcia G et al.: Analysis of hepatitis C viral quasispecies in liver transplantation. Transplantation Proc. 35(5), 1838-1840 (2003).
131. Schvoerer E, Soulier E, Royer C et al.: Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J. Infect. Dis. 196(4), 528-536 (2007).
132. Fafi-Kremer S, Fofana I, Soulier E et al.: Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 207(9), 2019-2031 (2010). Provides mechanisms for viral variant selection and antibody neutralization evasion and evidence for viral entry as a potential target for preventing HCV re-infection of the liver graft in transplant setting.
133. Jiang L, Yan LN: Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J. Gastroenterol. 16(20), 2468-2475 (2010).
134. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK: Current management of hepatitis B virus infection before and after liver transplantation. Liver Int. 29(9), 1294-1305 (2009).
135. Roche B, Samuel D: Evolving strategies to prevent HBV recurrence. Liver Transpl. 10(10 Suppl. 2), S74-S85 (2004).
136. Seong YR, Choi S, Lim JS, Lee CH, Lee CK, Im DS: Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. Vaccine 19(20-22), 2955-2964 (2001).
137. Meunier JC, Russell RS, Goossens V et al.: Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82(2), 966-973 (2008).
138. Catanese MT, Graziani R, von Hahn T et al.: High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 81(15), 8063-8071 (2007).
139. Fofana I, Krieger SE, Grunert F et al.: Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139(3), 953-964 E1-E4 (2010).
140. Zeisel MB, Cosset FL, Baumert TF: Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48(1), 299-307 (2008).
141. Johansson DX, Voisset C, Tarr AW et al.: Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl Acad. Sci. USA 104(41), 16269-16274 (2007).
142. Keck ZY, Olson O, Gal-Tanamy M et al.: A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J. Virol. 82(12), 6067-6072 (2008).
143. Owsianka AM, Tarr AW, Keck ZY et al.: Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89(Pt 3), 653-659 (2008).
144. Mancini N, Diotti RA, Perotti M et al.: Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PloS ONE 4(12), E8254 (2009).
145. Ploss A, Khetani SR, Jones CT et al.: Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl Acad. Sci. USA 107(7), 3141-3145 (2010).